Break it Down: Neurizon secures Australian patent for its lead ALS drug candidate
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, host Tylah Tully unpacks the latest news from Neurizon Therapeutics (ASX:NUZ), which has secured a new Australian patent for its lead drug candidate, NUZ-001 for treating neurodegenerative diseases including ALS, Alzheimer’s, Huntington’s and Parkinson’s.
Watch the video for more.
While Neurizon Therapeutics is a Stockhead advertiser, it did not sponsor this content.
Related Topics
Related Stories
UNLOCK INSIGHTS
Discover the untold stories of emerging ASX stocks.
Daily news and expert analysis, it's free to subscribe.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
